The comments need to be submitted to the Competition Commission of India within 15 days, along with supporting documents on how the merger can adversely impact the concerned person or entity, the regulator said, while adding that it would not consider 'unsubstantiated objections' to the deal.
The CCI said the public consultation process has been launched ‘in order to determine whether the combination has or is likely to have an appreciable adverse effect on competition in the relevant market in India’.
Widening its scrutiny of the multi-billion dollar deal, CCI had asked the two pharma majors on August 27 to make public specific details of their proposed merger.
This is the first instance where the CCI has ordered a public scrutiny of a proposed merger and acquisition deal to ensure compliance to fair trade regulations.
Sun Pharma and Ranbaxy, which had announced a $4-billion deal in April this year, were asked to make public details of their proposed transaction in a ‘prescribed format;, which has been now put in public domain for ‘comments/objections/suggestions’
Ranbaxy sale shows risk in Japanese M&A adventures
Big leap for Sun Pharma, Sunshine for Ranbaxy
Attention, Mr CM! Srinagar residents pool in money for flood control
Aviation minister to talk to states on jet fuel tax
How India can escape the dry spell doom